# Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

> **NCT00555724** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 40 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BIIB022

## Key facts

- **NCT ID:** NCT00555724
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555724, "Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00555724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*